Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiac function in mild and severe primary hypothyroidism

E C Ridgway, P W Ladenson, D S Cooper

    Life Sciences
    |February 15, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations.

    Diabetes, obesity & metabolism·2015
    Same author

    Reprint of: policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich et al.

    Hormones and behavior·2013
    Same author

    Reprint of: policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich, et al.

    Frontiers in neuroendocrinology·2013
    Same author

    Policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich et al.

    Andrology·2013
    Same author

    Policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich et al.

    Hormone research in paediatrics·2013
    Same author

    Policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich et al.

    European journal of endocrinology·2013

    Thyroid hormone replacement therapy significantly improves cardiac function in patients with hypothyroidism. Even mild cases show reversible left ventricular performance abnormalities with treatment, highlighting the importance of optimal thyroid hormone levels for heart health.

    Area of Science:

    • Cardiology
    • Endocrinology
    • Internal Medicine

    Background:

    • Primary hypothyroidism, ranging from mild to severe, can affect cardiac function.
    • Noninvasive techniques are crucial for assessing left ventricular performance in these patients.

    Purpose of the Study:

    • To analyze left ventricular performance abnormalities in 100 patients with primary hypothyroidism.
    • To determine the correlation between cardiac function and serum T4 levels.
    • To evaluate the reversibility of cardiac dysfunction with thyroid hormone therapy.

    Main Methods:

    • Analysis of 100 patients with primary hypothyroidism (mild to severe).
    • Utilized noninvasive techniques to assess left ventricular performance.
    • Monitored cardiac function in relation to serum thyroxine (T4) levels and thyroid-stimulating hormone (TSH) secretion.

    Related Experiment Videos

    Main Results:

    • Significant left ventricular performance abnormalities were observed, inversely correlating with serum T4 levels.
    • Cardiac dysfunction was completely reversible with thyroid hormone therapy (L-T4 or L-T3).
    • Even subclinical hypothyroidism showed improved cardiac function with TSH-normalized thyroid hormone doses; L-T3 was effective at lower doses than L-T4.

    Conclusions:

    • Thyroid hormone therapy effectively reverses cardiac abnormalities in hypothyroidism.
    • Optimal treatment strategies should consider normalizing TSH secretion for improved cardiac function.
    • L-T3 may offer advantages in achieving cardiac normalization at lower doses compared to L-T4.